Clinical Trial Update: Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immunogenicity of a melanoma DNA vaccine delivered via electroporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Uveal Melanoma

Drugs mentioned

• Melanoma DNA Vaccine (electroporation)

Snippet

Sponsor: Ichor Medical Systems Incorporated | Conditions: Melanoma (Skin), Intraocular Melanoma | Phase 1 | Status: COMPLETED